SY-2101 for APL

SY-2101: An Approach to Dramatically Reduce the Treatment Burden for APL Patients

SY-2101: An Approach to Dramatically Reduce the Treatment Burden for APL Patients

SY-2101 is a novel oral form of arsenic trioxide (ATO) previously in development for acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML) that is caused by a fusion of the RARA and PML genes. We are currently investing our resources solely on advancing tamibarotene through late-stage clinical development to market, and therefore we are not investing in this program at this time.

Opportunity to Set a New Standard of Care in Newly Diagnosed APL Patients

An intravenously administered formulation of ATO is part of a combination regimen that cures more than 80% of APL patients, but it is extremely burdensome on patients. The regimen requires up to 140 lengthy infusions over the course of a year. We believe that an oral form of ATO that offers similar efficacy to IV ATO would dramatically reduce the treatment burden on patients and improve access.